Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 7/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.39 |
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10706473 | 0.85 | AKT1 (0.47) | AKT1ALOX5PDPK1PHLPP1ILK | |
| SCHEMBL4779936 | 0.82 | ALOX5 (0.47) | AKT1ALOX5PDPK1PHLPP1ILK | |
| SCHEMBL407517 | 0.78 | AKT1 (0.65) | AKT1ALOX5PDPK1PHLPP1ILK | |
| SCHEMBL29393858 | 0.78 | AKT1 (0.65) | AKT1ALOX5PDPK1PHLPP1ILK | |
| SCHEMBL5441388 | 0.78 | AKT1 (0.65) | AKT1ALOX5PDPK1PHLPP1ILK | |
| SCHEMBL3270839 | 0.78 | AKT1 (0.65) | AKT1ALOX5PDPK1PHLPP1ILK | |
| SCHEMBL5770011 | 0.78 | ALOX5 (0.46) | AKT1ALOX5PDPK1PHLPP1ILK | |
| SCHEMBL30461429 | 0.75 | ALOX5 (0.71) | AKT1ALOX5NR1I2PPARGPPARA | |
| SCHEMBL4639828 | 0.75 | ALOX5 (0.71) | AKT1ALOX5NR1I2PPARGPPARA | |
| SCHEMBL969505 | 0.74 | ALOX5 (0.45) | AKT1ALOX5PDPK1PHLPP1ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004045534-A2 | CHROMAN DERIVATIVES FOR THE REDUCTION OF INFLAMMATION SYMPTOMS | GALILEO PHARMACEUTICALS, INC. (US) | 2004-06-03 | — | — | WO | claimed |
| US-20040097433-A1 | Chroman derivatives for the reduction of inflammation symptoms | MONSANTO TECHNOLOGY LLC | 2004-05-20 | — | — | US | claimed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2004045534-A2 | CHROMAN DERIVATIVES FOR THE REDUCTION OF INFLAMMATION SYMPTOMS | GALILEO PHARMACEUTICALS, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040097433-A1 | Chroman derivatives for the reduction of inflammation symptoms | MONSANTO TECHNOLOGY LLC | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | AKT1 3301/4885ALOX5 1992/4885PDPK1 1893/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | AKT1 3502/4885ALOX5 1604/4885PDPK1 2127/4885 |
| US-20040097433-A1 | Chroman derivatives for the reduction of inflammation symptoms | CCL2, MPO, MB | AKT1 4329/4885ALOX5 1449/4885PDPK1 2675/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | AKT1 3502/4885ALOX5 1604/4885PDPK1 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.